{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:34:45Z","timestamp":1795127685399,"version":"4.10.3"},"reference-count":31,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor\u2013associated hemophagocytic lymphohistiocytosis (HLH)\u2013like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and\/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger outcomes analyses of children and young adults (CAYAs) with B-ALL who develop these toxicities after the administration of commercially available tisagenlecleucel are not described. Using a multi-institutional database of 185 CAYAs with B-ALL, we conducted a retrospective cohort study including groups that developed HLH-LTs, high-grade (HG) CRS without HLH-LTs, or no to low-grade (NLG) CRS without HLH-LTs. Primary objectives included characterizing the incidence, outcomes, and preinfusion factors associated with HLH-LTs. Among 185 CAYAs infused with tisagenlecleucel, 26 (14.1%) met the criteria for HLH-LTs. One-year overall survival and relapse-free survival were 25.7% and 4.7%, respectively, in those with HLH-LTs compared with 80.1% and 57.6%, respectively, in those without. In multivariable analysis for death, meeting criteria for HLH-LTs carried a hazard ratio of 4.61 (95% confidence interval, 2.41-8.83), controlling for disease burden, age, and sex. Patients who developed HLH-LTs had higher pretisagenlecleucel disease burden, ferritin, and C-reactive protein levels and lower platelet and absolute neutrophil counts than patients with HG- or NLG-CRS without HLH-LTs. Overall, CAYAs with B-ALL who developed HLH-LTs after tisagenlecleucel experienced high rates of relapse and nonrelapse mortality, indicating the urgent need for further investigations into prevention and optimal management of patients who develop HLH-LTs after tisagenlecleucel.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008893","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T18:57:05Z","timestamp":1677697025000},"page":"2758-2771","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"first","affiliation":[{"name":"1Cancer and Blood Disorders Institute, Johns Hopkins All Children\u2019s Hospital, St. Petersburg, FL"},{"name":"2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Si Lim","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Pediatrics, John A. Burns School of Medicine, University of Hawai\u2019i at Manoa, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-8648","authenticated-orcid":false,"given":"Kyle","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"4Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai\u2019i at Manoa, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dreyzin","sequence":"additional","affiliation":[{"name":"5Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-0490","authenticated-orcid":false,"given":"Anant","family":"Vatsayan","sequence":"additional","affiliation":[{"name":"5Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[{"name":"4Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai\u2019i at Manoa, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baggott","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-3087","authenticated-orcid":false,"given":"Snehit","family":"Prabhu","sequence":"additional","affiliation":[{"name":"7Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Pacenta","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, University of Texas Southwestern Medical Center\/Children\u2019s Health, Dallas, TX"},{"name":"9Division of Hematology and Oncology, Cook Children\u2019s Medical Center, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Philips","sequence":"additional","affiliation":[{"name":"10Division of Pediatrics, University of Cincinnati, Cincinnati, OH"},{"name":"11Cincinnati Children\u2019s Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-9883","authenticated-orcid":false,"given":"Jenna","family":"Rossoff","sequence":"additional","affiliation":[{"name":"12Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Stefanski","sequence":"additional","affiliation":[{"name":"13National Marrow Donor Program\/Be the Match, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An","family":"Talano","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children\u2019s Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children\u2019s Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-5917","authenticated-orcid":false,"given":"Michael","family":"Verneris","sequence":"additional","affiliation":[{"name":"15University of Colorado School of Medicine, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Myers","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Oncology and Blood and Marrow Transplantation, Children\u2019s Mercy Hospital, University of Missouri Kansas City, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Karras","sequence":"additional","affiliation":[{"name":"17Department of Pediatrics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-1069","authenticated-orcid":false,"given":"Patrick","family":"Brown","sequence":"additional","affiliation":[{"name":"18Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-1683","authenticated-orcid":false,"given":"Challice L.","family":"Bonifant","sequence":"additional","affiliation":[{"name":"18Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"19Division of Pediatric Hematology\/Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Emory University and Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2679","authenticated-orcid":false,"given":"Michelle","family":"Hermiston","sequence":"additional","affiliation":[{"name":"20University of California San Francisco Benioff Children's Hospital, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[{"name":"21Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Krupski","sequence":"additional","affiliation":[{"name":"10Division of Pediatrics, University of Cincinnati, Cincinnati, OH"},{"name":"11Cincinnati Children\u2019s Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Keating","sequence":"additional","affiliation":[{"name":"15University of Colorado School of Medicine, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne H. C.","family":"Baumeister","sequence":"additional","affiliation":[{"name":"22Division of Pediatric Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"23Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"24Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-1141","authenticated-orcid":false,"given":"Vanessa A.","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"15University of Colorado School of Medicine, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Chinnabhandar","sequence":"additional","affiliation":[{"name":"25Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egeler","sequence":"additional","affiliation":[{"name":"7Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mavroukakis","sequence":"additional","affiliation":[{"name":"7Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-9956","authenticated-orcid":false,"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[{"name":"26Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"27Department of Pediatrics, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA"},{"name":"28Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA"},{"name":"29Department of Medicine, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[{"name":"30Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"31Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"5","key":"2023062614031809100_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2023062614031809100_bib2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023062614031809100_bib3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023062614031809100_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"6","key":"2023062614031809100_bib5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"2023062614031809100_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2023062614031809100_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2023062614031809100_bib8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2023062614031809100_bib9","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023062614031809100_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 15","key":"2023062614031809100_bib11","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023062614031809100_bib12","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"2023062614031809100_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023062614031809100_bib14","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023062614031809100_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023062614031809100_bib16","doi-asserted-by":"crossref","first-page":"73.e1","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2023062614031809100_bib17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023062614031809100_bib18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis: highly elevated ferritin levels and HLH","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2023062614031809100_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023062614031809100_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2023062614031809100_bib21","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2023062614031809100_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2021-148013","article-title":"Poor clinical outcome in pediatric immunotherapy is mediated by a pre-existing overactive IL-18-IFNy immune phenotype","volume":"138","author":"Burleigh","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2023062614031809100_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023062614031809100_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers10040104","article-title":"The critical role of inflammation in the pathogenesis and progression of myeloid malignancies","volume":"10","author":"Craver","year":"2018","journal-title":"Cancers"},{"issue":"10","key":"2023062614031809100_bib25","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/cancers12102789","article-title":"Interleukin-18 and hematopoietic recovery after allogeneic stem cell transplantation","volume":"12","author":"Radujkovic","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"2023062614031809100_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"2023062614031809100_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2023062614031809100_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2023062614031809100_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A\u00a0phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023062614031809100_bib30","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023062614031809100_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2758\/2060087\/blooda_adv-2022-008893-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2758\/2060087\/blooda_adv-2022-008893-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:06:36Z","timestamp":1687788396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/12\/2758\/494746\/HLH-like-toxicities-predict-poor-survival-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008893","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}